Pediatrics Doctors in New Baltimore, MI Accepting Medicare
6 Pediatrics doctors found. Showing 1 - 6
 Kevin Alan Kutskill, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 35054 23 Mile Rd, 101, New Baltimore, MI 48047 Phone: 586-725-2670 Fax: 586-725-3347 |
William D. Smyka, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 35054 23 Mile Rd, 101, New Baltimore, MI 48047 Phone: 586-725-2670 Fax: 586-725-3347 |
 Dr. Nicole Marie Beliveau, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 35054 23 Mile Rd, Suite 101, New Baltimore, MI 48047 Phone: 586-725-2670 |
Carol Fredal Abiragi, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 35054 23 Mile Rd, 101, New Baltimore, MI 48047 Phone: 586-725-2670 Fax: 586-725-3347 |
Roger Abiragi, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 35054 23 Mile Rd, 101, New Baltimore, MI 48047 Phone: 586-725-2670 Fax: 586-725-3347 |
Minda P Alimario, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 35054 23 Mile Rd, 101, New Baltimore, MI 48047 Phone: 586-725-2670 Fax: 586-725-3347 |
News Archive
RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation
RepRegen™, the ‘smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.
New technology to measure the sensitivity of nerve fibers that wire up the brain during development
Researchers at Georgetown University have developed a novel technology to precisely measure the sensitivity of nerve fibers that wire up the brain during development. Through use of this technology, they discovered that these fibers, or axons, possess an incredible sensitivity to molecular guidance cues that direct the axon's route to its desired destination in the brain.
Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.
Applied Brain Research exhibits Intel's newest neuromorphic research chip at OCE Discovery 2018
In a Canadian first, Applied Brain Research Inc., and Ontario Centres of Excellence are pleased to announce that Intel's newest neuromorphic research chip, Loihi, will be demonstrated live at this year's Discovery conference.
› Verified 4 days ago